Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Diagnosis of adenocarcinoma of the prostate
• •* Osseous metastases confirmed by radiography
• •* Lytic bone lesions considered for biopsy if there is clinical suspicion of histologic conversion to small cell carcinoma
• •Failed prior hormonal therapy
• •Progressive disease, as evidenced by one of the following:
• •* 2 consecutive rises in prostate-specific antigen (PSA) of at least 1 ng/mL over 4 weeks
• •* Increase of 25% of the product of bidimensional disease or 30% in maximum diameter
• •* Increase in number of osseous metastases by bone scan
• •* Worsening symptoms attributable to disease progression (e.g., worsening bony pain)
• •PSA ≥ 1 ng/mL
• •Castrate serum testosterone ≤ 50 ng/dL
• •* Concurrent luteinizing-hormone releasing-hormone analog required for medically castrated patients
• •No small cell or sarcomatoid prostate cancers
• •No uncontrolled CNS metastases
• •PATIENT CHARACTERISTICS:
• •Age
• •Any age
• •Performance status
• •Eastern Cooperative Oncology Group (ECOG) 0-2
• •Life expectancy
• •At least 3 months
• •Hematopoietic
• •Absolute granulocyte count ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •Hepatic
• •Bilirubin ≤ 1.5 mg/dL
• •Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤ 2 times upper limit of normal
• •No chronic liver disease
• •Renal
• •Creatinine clearance ≥ 40 mL/min
• •Cardiovascular
• •No New York Heart Association class III or IV congestive heart failure
• •No unstable angina
• •No myocardial infarction within the past 6 months
• •No evidence of myocardial ischemia on electrocardiogram
• •No uncontrolled severe hypertension
• •Pulmonary
• •No oxygen-dependent lung disease
• •Other
• •HIV negative
• •No concurrent severe infection
• •No contraindication to corticosteroids
• •No uncontrolled diabetes mellitus
• •No grade 2 or greater peripheral neuropathy
• •No other malignancy within the past 2 years except nonmelanoma skin cancer
• •No overt psychosis, mental disability, or incompetency that would preclude giving informed consent
• •No history of noncompliance
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •No concurrent immunotherapy
• •Chemotherapy
• •No prior taxanes
• •No more than 2 prior chemotherapy regimens
• •At least 30 days since prior chemotherapy and recovered
• •No other concurrent chemotherapy
• •Endocrine therapy
• •See Disease Characteristics
• •At least 4 weeks since prior flutamide or nilutamide\*
• •At least 6 weeks since prior bicalutamide\* NOTE: \*Unless there is evidence of interim disease progression
• •Radiotherapy
• •At least 90 days since prior strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium and recovered
• •At least 30 days since other prior radiotherapy and recovered
• •Surgery
• •Fully recovered from prior surgery
• •Other
• •No concurrent ketoconazole
• •No concurrent warfarin